Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Chakravarty

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.
Rheumatology (Oxford, England)|September 14, 2022
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
Joint Bone Spine|January 27, 2023
Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and EuropeJessica A Walsh, Alexis Ogdie, Kaleb Michaud, et al.
Clinical Rheumatology|July 21, 2021
Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020A M Orbai, S M Reddy, N Dennis, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Drugs - Real World Outcomes|July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor InhibitorsJessica A Walsh, Iris Lin, Ruizhi Zhao, et al.
Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Clinical Rheumatology|March 3, 2021
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trialAlexis Ogdie, Jessica A Walsh, Soumya D Chakravarty, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Rheumatology and Therapy|August 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.
Rheumatology (Oxford, England)|September 14, 2022
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
Joint Bone Spine|January 27, 2023
Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and EuropeJessica A Walsh, Alexis Ogdie, Kaleb Michaud, et al.
Clinical Rheumatology|July 21, 2021
Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020A M Orbai, S M Reddy, N Dennis, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Drugs - Real World Outcomes|July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor InhibitorsJessica A Walsh, Iris Lin, Ruizhi Zhao, et al.
Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Clinical Rheumatology|March 3, 2021
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trialAlexis Ogdie, Jessica A Walsh, Soumya D Chakravarty, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Rheumatology and Therapy|August 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
Pageof 10